IA Trial Radar
L'essai clinique NCT06735521 (CMR_TCPC) pour Cœur univentriculaire, Dysfonctionnement microvasculaire, Insuffisance cardiaque, Magnetic Resonance est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation (CMR_TCPC)

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT06735521 (CMR_TCPC) est un essai observationnel pour Cœur univentriculaire, Dysfonctionnement microvasculaire, Insuffisance cardiaque, Magnetic Resonance. Son statut actuel est : en recrutement. L'étude a débuté le 15 avril 2024 et vise à recruter 30 participants. Dirigé par l'Institut Karolinska, l'essai devrait être terminé d'ici le 1 septembre 2025. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 16 décembre 2024.
Résumé succinct
Univentricular heart (UVH) is a severe congenital heart disease. Accurate advanced non-invasive diagnostic methods is limited. Cardiovascular magnetic resonance (CMR) imaging has evolved as a particularly useful tool for the study of patients with adult congenital heart disease (ACHD) considering its ability to determine detailed anatomy and detect early cardiac dysfunction without the need for radiation exposure. Most of contemporary treatment recommendations are based on consensus opinions/documents and small studies from local, or national registries. Improved knowledge is needed in all these areas to facilitate clinical decisions regarding treatment, monitoring and follow-up.

This study seeks to answer if early detection of deterioration in cardiac function, venous pressure and microvascular dysfunction can identify patients before the symptoms progress and thus help to initiate early treatment. The hypothesis is that quantitative myocardial stress-perfusion maps improves the pathophysiological insight in patients with UVH.

The overall goal with this research proposal is to implement combined advanced CMR imaging for a comprehensive non-invasive mapping of functional cardiovascular behavior in patients with complex UVH disease. The outcome of this research may benefit this young adult patient population due to early detection of cardiac disease, less hospitalizations because of heart failure, and eventually decrease morbidity and mortality.

Description détaillée
CMR is performed supine with a Magnetom Aera® 1.5 Tesla (T) scanner (Siemens Healthcare, Erlangen, Germany), with a phased-array 18-channel body matrix coil and a spine matrix coil. A venous blood sample is drawn to determine hematocrit and blood creatinine prior to imaging. Full coverage retrospective electrocardiographic (ECG)-gated balanced steady state free precession (bSSFP) cine imaging is acquired in standard three long-axis and short-axis slices. Typical imaging parameters are flip angle 68°, pixel size 1.4 × 1.9 mm2, slice thickness 8.0 mm, echo time (TE)/repetition time (TR) 1.19/37.05 ms, matrix size 256 × 144 and field of view (FOV) 360 × 270 mm2.

Using first-pass perfusion imaging, quantitative perfusion maps (ml/min/g) are acquired in one short-axis and one long-axis slice (mid-ventricular, 2-chamber) during administration of an intravenous contrast-agent bolus (0.05 mmol/kg, gadobutrol, Gadovist, Bayer AB, Solna, Sweden), during adenosine infusion (110 µg/kg/min or increased according to clinical routine to 140 µg/kg/min in the absence of adequate response to adenosine (Adenosine, Life Medical AB, Stockholm) and in subsequent rest. Adenosine response is assessed clinically based on symptoms and heart rate response. Adenosine and contrast agent are administered in two different cannulas. Subjects abstained from caffeine for 24 hours prior to CMR examination. A distributed tissue exchange model is used to compute the perfusion maps and the Gadgetron (reconstruction computer) inline perfusion mapping software is used to generate the perfusion maps.Typical imaging parameters were bSSFP single shot readout, flip angel 50°, slice thickness 8.0 mm, TE/TR 1.04/2.5 ms, bandwidth 1085 Hz/pixel, FOV 360 × 270 mm2 and saturation delay/trigger delay (TD) 95/40 ms.

Titre officiel

Att Överleva Och Leva Som Vuxen Med Enkammarhjärta I Sverige

Conditions
Cœur univentriculaireDysfonctionnement microvasculaireInsuffisance cardiaqueMagnetic Resonance
Publications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:
Autres identifiants de l'essai
  • CMR_TCPC
  • Dnr 2022-04574-01
Numéro NCT
Date de début (réel)
2024-04-15
Dernière mise à jour publiée
2024-12-16
Date de fin (estimée)
2025-09-01
Inscription (estimée)
30
Type d'essai
Observationnel
Statut
En recrutement
Mots clés
Fontan circulation
CMR
stress-perfusion
tissue characterization
univentricle heart
TCPC
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
Univentricle heart, operated with TCPC (total cavo pulmonary connection)
Cardiac Magnetic Resonance Stress-perfusion
Included patients will be examined at the Karolinska University Hospital in a 1.5T Siemens Sola magnetic resonance camera at rest and during adenosine stress with specific CMR sequences (adenosine stress-perfusion, myocardial velocities, and tissue characterization) for non-invasive determination of macro- and microvascular dysfunction, global myocardial function, pulmonary artery pressure and scarring of the myocardium. Adenosine or Regadenoson will be used as stress medication which is according to clinical routine. Adenosine will be infused over approximately 5 minutes (110-140 μg / kg/min), Regadenoson (5 ml) will be a 10-second injection (400 μg single dosage). Intravenous gadolinium-based contrast agents will be administered, Gadovist (1 mmol/ml, gadobuterol), 0.15 mmol/kg during stress and rest.
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Detection of microvascular dysfunction in patients with UVH
This project aims to evaluate microvascular dysfunction using quantitative stress-perfusion CMR in patients with different morphological systemic chamber (left vs right).
Through study completion, an average of 1 year
Critère secondaire d'évaluation
Critères d'évaluationDescription de critèresPériode
To detect and compare tissue characterization.
Investigate whether positive findings in tissue characterization is higher in different systemic ventricles (left vs right) using T1 and T2-mapping, LGE (late gadolinium enhancement, myocardial scar).
Through study completion, an average of 1 year
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous
  • Patients who had undergone total cavo-pulmonary connection (TCPC) surgery resulting in Fontan circulation.
  • NYHA (New York Heart Assosiation) class I-II.
  • Understanding the study information (signed informed consent).
  • >18 years old.

  • Device therapy (pacemaker, ICD).
  • Failing Fontan (NYHA III-IV).
  • Kidney failure (GFR<30ml/h).
  • Arrythmia (atrial fibrillation).
  • Pregnancy.
Karolinska Institutet logoInstitut Karolinska
Karolinska University Hospital logoKarolinska University Hospital
Partie responsable de l'essai
Peder Sörensson, Investigateur principal, Senior Consultant in Cardiology, Karolinska Institutet
Contact central de l'essai
Contact: Peder Sorensson, MD, Associate professor, +46 731 400059, [email protected]
Contact: Ayse-Gul Ozturk, MD, [email protected]
1 Centres de l'essai dans 1 pays
Karolinska University Hospital, Stockholm, 17176, Sweden
Peder Sorensson, MD, Associate professor, Contact, +46 731 400059, [email protected]
Ayse-Gul Ozturk, MD, Contact, +46 72 578 02 72, [email protected]
Peder Sorensson, MD, Associate professor, Contact
En recrutement